JP2018516539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516539A5 JP2018516539A5 JP2017553320A JP2017553320A JP2018516539A5 JP 2018516539 A5 JP2018516539 A5 JP 2018516539A5 JP 2017553320 A JP2017553320 A JP 2017553320A JP 2017553320 A JP2017553320 A JP 2017553320A JP 2018516539 A5 JP2018516539 A5 JP 2018516539A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- group
- sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000012453 solvate Substances 0.000 claims description 22
- 239000003053 toxin Substances 0.000 claims description 21
- 231100000765 toxin Toxicity 0.000 claims description 20
- 229940127089 cytotoxic agent Drugs 0.000 claims description 18
- 239000002254 cytotoxic agent Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 5
- -1 iodo-acetyl Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 210000004602 germ cell Anatomy 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 claims 2
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 150000005415 aminobenzoic acids Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000001293 nucleolytic effect Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 description 56
- 229920005654 Sephadex Polymers 0.000 description 17
- 239000012507 Sephadex™ Substances 0.000 description 17
- 239000003480 eluent Substances 0.000 description 16
- 238000011033 desalting Methods 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 238000001914 filtration Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 description 4
- YSRHEJDCILVGQN-UHFFFAOYSA-N C(C)(=O)SCCC=C=O Chemical compound C(C)(=O)SCCC=C=O YSRHEJDCILVGQN-UHFFFAOYSA-N 0.000 description 4
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 4
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 102100031013 Transgelin Human genes 0.000 description 4
- NLMBVBUNULOTNS-HOKPPMCLSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o Chemical compound C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN3C(C=CC3=O)=O)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 NLMBVBUNULOTNS-HOKPPMCLSA-N 0.000 description 4
- IADUWZMNTKHTIN-MLSWMBHTSA-N (2,5-dioxopyrrolidin-1-yl) 4-[[3-[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]methyl]cyclohexane-1-carboxylate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSC2CC(=O)N(CC3CCC(CC3)C(=O)ON3C(=O)CCC3=O)C2=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 IADUWZMNTKHTIN-MLSWMBHTSA-N 0.000 description 2
- 108091022873 acetoacetate decarboxylase Proteins 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010044540 auristatin Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- 101000797092 Mesorhizobium japonicum (strain LMG 29417 / CECT 9101 / MAFF 303099) Probable acetoacetate decarboxylase 3 Proteins 0.000 description 1
- 101710096655 Probable acetoacetate decarboxylase 1 Proteins 0.000 description 1
- 101710096660 Probable acetoacetate decarboxylase 2 Proteins 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510185602 | 2015-04-17 | ||
| CN201510185602.3 | 2015-04-17 | ||
| CN201510300885.1 | 2015-06-04 | ||
| CN201510300885.1A CN106188293A (zh) | 2015-04-17 | 2015-06-04 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| PCT/CN2016/078699 WO2016165580A1 (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516539A JP2018516539A (ja) | 2018-06-28 |
| JP2018516539A5 true JP2018516539A5 (OSRAM) | 2019-04-25 |
Family
ID=57459461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553320A Pending JP2018516539A (ja) | 2015-04-17 | 2016-04-07 | 抗ｃ−Ｍｅｔ抗体および抗ｃ−Ｍｅｔ抗体−細胞毒性薬物複合体ならびにそれらの医薬用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10543284B2 (OSRAM) |
| EP (1) | EP3284751A4 (OSRAM) |
| JP (1) | JP2018516539A (OSRAM) |
| KR (1) | KR20170138451A (OSRAM) |
| CN (3) | CN106188293A (OSRAM) |
| AU (1) | AU2016248357A1 (OSRAM) |
| BR (1) | BR112017021245A2 (OSRAM) |
| CA (1) | CA2982777A1 (OSRAM) |
| MX (1) | MX2017012965A (OSRAM) |
| RU (1) | RU2017135257A (OSRAM) |
| TW (1) | TWI731856B (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106794258B (zh) * | 2015-02-15 | 2019-07-12 | 江苏恒瑞医药股份有限公司 | 配体-细胞毒性药物偶联物、其制备方法及其应用 |
| AU2017223532A1 (en) * | 2016-02-26 | 2018-08-30 | Jiangsu Hengrui Medicine Co., Ltd. | New toxin and method for preparing intermediate thereof |
| RS60663B1 (sr) | 2016-05-17 | 2020-09-30 | Abbvie Biotherapeutics Inc | Konjugati anti-cmet antitelo-lek i metodi za njihovu primenu |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| US20180230218A1 (en) * | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| BR112019020174A2 (pt) | 2017-03-30 | 2020-06-02 | Jiangsu Hengrui Medicine Co., Ltd. | Método para preparar conjugado anticorpo-fármaco |
| CA3064470A1 (en) * | 2017-06-06 | 2018-12-13 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof |
| WO2018232349A1 (en) * | 2017-06-15 | 2018-12-20 | Development Center For Biotechnology | Antibody-drug conjugates containing anti-globo h antibodies and uses thereof |
| WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| CN110090306B (zh) * | 2018-01-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 双醛连接臂的配体-药物偶联物、其制备方法及其应用 |
| KR102221755B1 (ko) * | 2018-05-02 | 2021-03-02 | (주)에임드바이오 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
| WO2019242505A1 (zh) | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| MX2021003446A (es) * | 2018-09-30 | 2021-06-15 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Conjugado analogo del anticuerpo anti-bth3 y exatecan, y uso medicinal del mismo. |
| KR102396194B1 (ko) * | 2018-12-07 | 2022-05-10 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| US20230072897A1 (en) * | 2019-06-06 | 2023-03-09 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-b7-h4 antibody-drug conjugate and medicinal use thereof |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| CA3076714C (en) * | 2019-09-29 | 2021-06-15 | Mabplex International, Ltd. | Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof |
| CA3175048A1 (en) * | 2020-03-25 | 2021-09-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for antibody medicament conjugate |
| CN115279781B (zh) * | 2020-03-26 | 2025-05-09 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| CN116963782A (zh) * | 2020-05-03 | 2023-10-27 | 联宁（苏州）生物制药有限公司 | 包含抗trop-2抗体的抗体药物偶联物 |
| CN111892656B (zh) * | 2020-08-10 | 2021-02-19 | 北京鼎成肽源生物技术有限公司 | 抗人c-Met人鼠嵌合单克隆抗体及其应用 |
| US20220056111A1 (en) * | 2020-08-11 | 2022-02-24 | Yurogen Biosystems Llc | MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOF |
| KR20230018454A (ko) * | 2020-09-01 | 2023-02-07 | 레메젠 코, 리미티드 | 항-c-Met 항체-약물 접합체 및 이의 용도 |
| CN116472064A (zh) * | 2020-10-12 | 2023-07-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| CN112683857B (zh) * | 2021-01-06 | 2022-10-14 | 上海药明生物医药有限公司 | 一种通过评估分析物的溶剂效应对亲和力实验的影响来指导spr检测前处理的方法 |
| CN112924665B (zh) * | 2021-02-19 | 2023-10-03 | 山东莱博生物科技有限公司 | 一种抗体辣根过氧化物酶标记物及其制备与应用 |
| KR20230152069A (ko) * | 2021-02-25 | 2023-11-02 | 알리겐 그룹 | 효과기 분자를 포함하는 표적화 접합체 및 이의 용도 |
| WO2022205316A1 (en) * | 2021-04-01 | 2022-10-06 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising effector molecules and uses thereof |
| UY39743A (es) * | 2021-04-29 | 2022-11-30 | Abbvie Inc | Conjugados de anticuerpo anti-c-met y fármaco |
| EP4372001A4 (en) * | 2021-07-14 | 2025-02-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF |
| CN115975030B (zh) * | 2021-09-30 | 2023-09-26 | 杭州邦顺制药有限公司 | 抗cd39抗体-药物偶联物及其用途 |
| CN118159567A (zh) * | 2021-11-05 | 2024-06-07 | 正大天晴药业集团股份有限公司 | 抗c-Met抗体及其应用 |
| CN115963233B (zh) * | 2022-03-17 | 2025-06-03 | 南京药明康德新药开发有限公司 | 一种评估抗体偶联药物稳定性的方法 |
| TW202430566A (zh) * | 2022-11-24 | 2024-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種包含特異性結合ｈｇｆｒ和ｅｇｆｒ的雙特異性抗體的醫藥組成物 |
| WO2024131835A1 (en) * | 2022-12-20 | 2024-06-27 | Hansoh Bio Llc | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |
| TW202434637A (zh) * | 2022-12-20 | 2024-09-01 | 美商翰森生物有限責任公司 | 抗體、抗原結合片段及其醫藥用途 |
| WO2024131949A1 (zh) * | 2022-12-23 | 2024-06-27 | 苏州宜联生物医药有限公司 | Anti-cMet抗体、抗体药物偶联物及其制备方法和用途 |
| AU2023448948A1 (en) * | 2023-05-24 | 2025-10-09 | Hangzhou Dac Biotech Co., Ltd | Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate |
| WO2025021151A1 (zh) * | 2023-07-25 | 2025-01-30 | 江苏恒瑞医药股份有限公司 | 靶向c-Met的抗体-药物偶联物及其医药用途 |
| WO2025060962A1 (en) * | 2023-09-21 | 2025-03-27 | Beijing Neox Biotech Limited | Multi-specific antibodies and uses thereof |
| CN120025446A (zh) * | 2023-11-23 | 2025-05-23 | 上海橙帆医药有限公司 | 结合分子及抗体药物偶联物和用途 |
| WO2025146620A1 (ko) * | 2024-01-02 | 2025-07-10 | 주식회사 종근당 | 항 c-met 항체를 포함하는 항암 조합물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2357006E (pt) * | 2002-07-31 | 2016-01-22 | Seattle Genetics Inc | Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa |
| SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| RU2398777C2 (ru) * | 2004-08-05 | 2010-09-10 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| AR078470A1 (es) * | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
| KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| US9994644B2 (en) * | 2013-04-30 | 2018-06-12 | Agency For Science, Technology And Research | mAB 2 anti-Met antibody |
-
2015
- 2015-06-04 CN CN201510300885.1A patent/CN106188293A/zh active Pending
-
2016
- 2016-04-07 JP JP2017553320A patent/JP2018516539A/ja active Pending
- 2016-04-07 BR BR112017021245-5A patent/BR112017021245A2/pt not_active Application Discontinuation
- 2016-04-07 EP EP16779555.8A patent/EP3284751A4/en not_active Withdrawn
- 2016-04-07 RU RU2017135257A patent/RU2017135257A/ru not_active Application Discontinuation
- 2016-04-07 US US15/565,928 patent/US10543284B2/en active Active
- 2016-04-07 MX MX2017012965A patent/MX2017012965A/es unknown
- 2016-04-07 KR KR1020177031260A patent/KR20170138451A/ko not_active Withdrawn
- 2016-04-07 CN CN201910217709.XA patent/CN111196853A/zh active Pending
- 2016-04-07 CN CN201680001857.2A patent/CN106687480B/zh active Active
- 2016-04-07 AU AU2016248357A patent/AU2016248357A1/en not_active Abandoned
- 2016-04-07 CA CA2982777A patent/CA2982777A1/en not_active Abandoned
- 2016-04-15 TW TW105111792A patent/TWI731856B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516539A5 (OSRAM) | ||
| RU2017135257A (ru) | Антитело к с-мет и конъюгат антитело к с-мет-цитотоксическое лекарственное средство, и их фармацевтическое применение | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| US20250281631A1 (en) | Antibody-drug conjugates and preparation methods and use thereof | |
| TWI895608B (zh) | 抗c-Met抗體藥物結合物 | |
| JP2024545233A (ja) | カンプトテシン化合物及びそのコンジュゲート | |
| US20220202947A1 (en) | Methods of preventing methionine oxidation in immunoconjugates | |
| TW202421204A (zh) | 抗體—藥物結合物及其製備方法及用途 | |
| RU2019107392A (ru) | Медицинское применение конъюгата антитело против c-met цитотоксическое лекарственное средство | |
| TWI864640B (zh) | Gpc3抗體藥物偶聯物及其用途 | |
| CN118302199A (zh) | 抗cdh6抗体及其抗体-药物偶联物 | |
| CN119053607A (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| CN119300868A (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| CN117534725A (zh) | 连接子、连接子-药物缀合物、配体-药物偶联物及其应用 | |
| KR20250112249A (ko) | 융합된 고리 화합물, 이의 접합체 및 이의 용도 | |
| KR20250106279A (ko) | 헤테로고리 화합물 및 이의 제조방법과 용도 | |
| WO2025045015A1 (zh) | 抗体-药物缀合物及其制备方法和用途 | |
| KR20250128359A (ko) | 항 b7h3 및 pd-l1의 이중특이성 항체-약물 접합체 및 이의 제조 방법과 용도 | |
| CN119074949A (zh) | 抗b7-h3的抗体或其片段以及靶向b7-h3的抗体药物偶联物 | |
| CN120923576A (zh) | 一种海兔毒素类似物及其配体偶联药物及其制备方法和应用 | |
| CN120771301A (zh) | 药物偶联物、抗体偶联物及用途 | |
| CN119954820A (zh) | 一种化合物及其应用 |